类麻症相关的肺高血压的表型 - - 一个具有挑战性的
Aneta Kacprzak1, Witold Tomkowski1, Monika Szturmowicz1
11st Department of Lung Diseases, National Tuberculosis and Lung Diseases Institute, Plocka 26, 01-138 Warsaw, Poland.
Diagnostics (Basel, Switzerland)
|October 14, 2023
概括
麻症相关的肺高血压 (SAPH) 是一种严重的并发症,流行病学和多因素原因不明. 建议根据表型量身定制SAPH管理,但由于知识差距和评估困难而具有挑战性.
科学领域:
- 肺部医学 肺部医学
- 心脏病学 心脏病学
- 类风湿病学 类风湿病学
背景情况:
- 沙丘病是肺高血压 (PH) 的已知危险因素.
- Sarcoidosis-associated pulmonary hypertension (SAPH) 是一种严重的并发症,影响患者的发病率和死亡率.
- 尚不完全了解SAPH的流行病学和病原性.
研究的目的:
- 总结关于SAPH的当前知识.
- 描述SAPH的不同表型.
- 为了突出SAPH表型化中面临的挑战,以进行量身定制的管理.
主要方法:
- 审查关于肉病和肺高血压的现有文献.
- 对促进SAPH的拟议病态机制的分析.
- 讨论有关SAPH表型的临床和病理因素.
主要成果:
- SAPH的发病是多因素的,涉及肺部疾病,外部压缩,血管病变和心脏功能障碍.
- 提出了SAPH表型,但精确的分类是困难的.
- 由于不完全的理解,死前评估的局限性和病情的动态性质,表型形成是复杂的.
结论:
- 了解SAPH表型对于个性化治疗策略至关重要.
- 在临床实践中准确表型SAPH存在重大挑战.
- 需要进一步的研究来阐明SAPH的病原性,并改进诊断方法.
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
194
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
194
Cardiomyopathy III: Hypertrophic Cardiomyopathy
16
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
176
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
176
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.8K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.8K
COPD: Pathogenesis and Clinical Features
309
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
309
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
177
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
177


